Noxafil (Posaconazole)

Posaconazole, the active ingredient in Noxafil, is an azole antifungal presented as an oral formulation for oral use. It is indicated for the treatment and prevention of invasive aspergillosis and invasive candidiasis, especially in immunocompromised patients such as those undergoing chemotherapy, stem‑cell transplantation, or receiving prolonged corticosteroid therapy.

GNH USA supplies Noxafil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Noxafil (posaconazole) is used to manage invasive fungal infections and to prevent opportunistic fungal disease in high‑risk patients. - Invasive aspergillosis: treatment of proven or probable infection in patients with hematologic malignancies or stem‑cell transplants. - Invasive candidiasis: treatment of candidemia and other forms of invasive candidiasis in adults. - Prophylaxis of fungal infections: prevention of aspergillosis and candidiasis in immunocompromised individuals receiving chemotherapy or prolonged corticosteroids.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools that may be watery. - Headache: transient cranial discomfort. - Elevated liver enzymes: increase in ALT/AST levels.

Serious or Rare Side Effects: - Hepatotoxicity: severe liver injury requiring monitoring. - QT interval prolongation: risk of cardiac arrhythmias. - Severe hypersensitivity reactions: including anaphylaxis. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: rare skin eruptions. - Visual disturbances: blurred vision or photophobia. - Severe hypertension: marked increase in blood pressure.

Precautions for Noxafil include careful assessment before initiating therapy. - Pregnancy Category C: use only if potential benefit justifies potential risk. - Liver function monitoring: check ALT/AST before and during treatment. - QT interval monitoring: avoid in patients with known prolongation or concurrent QT‑prolonging drugs. - Drug‑interaction awareness: review concomitant CYP3A4 substrates, inhibitors, and inducers. - Store at ambient temperature: keep below 25°C, protect from moisture and store in original packaging.

Posaconazole has several clinically relevant drug interactions. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin): may increase posaconazole exposure. - Drugs that prolong QT interval (e.g., quinidine, sotalol, amiodarone): heightened risk of arrhythmia. - HIV protease inhibitors (e.g., ritonavir): can raise plasma concentrations. Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin): may reduce efficacy. - Statins metabolized by CYP3A4 (e.g., simvastatin, lovastatin): increased risk of myopathy. - Oral contraceptives: reduced hormonal effectiveness, consider alternative contraception.